Microtubulin binding sites as target for developing anticancer agents

Area of Science:

• Cell Biology
• Biochemistry
• Pharmacology

Background:

• Microtubules (MTs) are essential for eukaryotic cell functions, including mitosis, cell motility, and intracellular transport.
• Alpha- and beta-tubulin, the primary components of MTs, are crucial for their dynamic instability and cellular roles.
• Tubulin is a validated target for anticancer drug development, with established agents like taxanes and vinca alkaloids.

Purpose of the Study:

• To review structure-activity relationships (SAR) of various antimitotic agents targeting tubulin.
• To highlight the need for novel natural analogs that interact with tubulin at distinct sites.
• To provide essential data for scientists involved in anticancer drug design.

Main Methods:

• Literature review of antimitotic agents and their interaction with tubulin.
• Analysis of structure-activity relationships (SAR) for different classes of tubulin-binding compounds.
• Compilation of data on natural analogs with antimitotic potential.

Main Results:

• Tubulin-binding molecules, including taxanes and vinca alkaloids, are effective antimitotic agents.
• Resistance to existing tubulin-targeting drugs necessitates the development of new agents.
• Various natural compounds exhibit antimitotic activity by interfering with tubulin dynamics.

Conclusions:

• Tubulin remains a critical target for developing novel anticancer therapeutics.
• Developing new antimitotic agents with unique binding mechanisms is essential to overcome drug resistance.
• SAR data on diverse tubulin-binding agents are vital for future drug discovery efforts in oncology.